Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Janus kinase inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure?

British journal of haematology - 1 May 2012

Harrison Claire, Verstovsek Srdan, McMullin Mary F, Mesa Ruben

Abstract excerpt

Following the discovery of the Janus kinase (JAK) 2 V617F mutation in 2005 the explosion of research and drug development activity has not only advanced our understanding of the pathogenesis of myeloproliferative neoplasms (MPNs) but also triggered debate about classification, allowed revised diagnostic and response criteria, provided a target for treatment and a mode of monitoring its success. These changes and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Janus Kinase 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinases

Share to Mutation

Share to Myeloproliferative Disorders

Share to Palliative Care

Share to Primary Myelofibrosis

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 22463737
DOI: 10.1111/j.1365-2141.2012.09108.x
PMCID: PMC8721529

Genes

JAK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Janus kinase inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure?PMID 22463737Read ↗

Janus kinase inhibition and symptom control in myeloproliferative neoplasmsSemantic proximity Read ↗

Janus kinase inhibitors for the treatment of myeloproliferative neoplasms.Semantic proximity Read ↗

Janus-Activated Kinase 2 Inhibitors: A New Era of Targeted Therapies Providing Significant Clinical Benefit for Philadelphia Chromosome–Negative Myeloproliferative NeoplasmsSemantic proximity Read ↗

JAK2 in Myeloproliferative Neoplasms: Still a ProtagonistSemantic proximity Read ↗

New insights into the pathogenesis and treatment of chronic myeloproliferative disorders.Semantic proximity Read ↗

Next-generation JAK inhibitors in the treatment of myeloproliferative neoplasms.Semantic proximity Read ↗

The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.Semantic proximity Read ↗

How many JAK inhibitors in myelofibrosis?Semantic proximity Read ↗

Management of Myelofibrosis: from Diagnosis to New Target Therapies.Semantic proximity Read ↗

Janus activated kinase inhibition in myelofibrosis.Semantic proximity Read ↗

SOHO State of the Art Updates and Next Questions: Is Combination Therapy Here for Myelofibrosis?Semantic proximity Read ↗

'JAK-ing' up the treatment of primary myelofibrosis: building better combination strategies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.